Rehabilitation Devices
Driven by the following and other factors, the medical rehabilitation industry in China is rapidly expanding.
– Accelerating population aging
– The continuous and steady growth of medical insurance funds
– Increase in the population of chronic disease
– Policy and financial support in disability rehabilitation
– Hierarchical diagnosis and treatment promote the development of primary medical institutions
According to KPMG’s report, in 2018, the total consumption of China’s rehabilitation medical market was RMB￥ 58.3 billion (approximately USD$ 8.3 billion). The compound growth rate is 26.9% from 2011 to 2018. It is estimated that the scale of the rehabilitation medical service market will reach RMB￥ 103.2 billion (approximately USD$ 14.7 billion) in 2021.
Submitted Projects:
Project ID: REH101
Category: Rehabilitation Devices/Drugs
Keyword: Insulin drugs
Project REH101 employs its proprietary excipient library, BioXxxx®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism
Indications: Diabetes and other metabolic diseases
Stage: Clinical Phase III
Partnering Objectives: Joint development, Commercial license
Country: France
Project ID: REH102
Category: Rehabilitation Devices/Drugs
Keyword: Artificial Intelligence Remote Treatment for Heart Failure
Project REH101 is committed to solving the huge clinical problem of heart failure rehospitalization. The company uses remote monitoring and AI algorithms to provide doctors and patients with the best diagnostic basis and medication control, effectively reducing the risk of heart failure patients with relapse and greatly reducing the frequency of hospitalization.
Indications: Cardiovascular diseases
Stage: Technology platform
Partnering Objectives: Fundraising, business cooperation
Country: France
Project ID: REH104
Category: Rehabilitation Devices/Drugs
Keyword: Protease activator
Project REH104 develops innovative treatments for metabolic disorders, including type 2 diabetes and NASH. With our partner Sumitomo Dainippon Pharma, we are conducting a Phase 3 program for Imeglimin for type 2 diabetes in Japan. Roivant Sciences is responsible for Imeglimin’s development and commercialization outside of Sumitomo Dainippon Pharma’s territories, including the US and Europe. PXL770, a direct adenosine monophosphate-activated protein kinase activator, is in Phase 2a for NASH and has the potential to treat additional metabolic diseases. PXL065, a mitochondrial pyruvate carrier inhibitor, is in Phase 1 for NASH. Poxel also has earlier-stage programs for metabolic, specialty and rare diseases.”
Indications: Type 2 diabetes, NASH non-alcoholic fatty liver
Stage: Phase III
Partnering Objectives: Lisencing
Country: France
Potential Chinese Partners:
